No Data
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
William Blair Remains a Buy on Cabaletta Bio (CABA)
Cabaletta Bio Advances Clinical Trials With Lonza Partnership
Cabaletta Bio Announces Strategic Priorities, Anticipated Milestones for 2025
Express News | Cabaletta Bio Inc: Unaudited Cash and Cash Equivalents as of Dec 31, 2024 Was $164 Mln
104742610 : not sure
104742610 : hold for long term